Singapore, Sept. 9 -- Japan-based Hodogaya Chemical has established a subsidiary to promote the nucleic acid therapeutics CDMO business. In its Mid-term Management Plan "CODE/CHORD 2030,", the company identified its entry into the nucleic acid therapeutics CDMO business as a new growth driver following its OLED materials business.

Published by HT Digital Content Services with permission from BioSpectrum Asia....